Literature DB >> 10873868

Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment.

E Coll1, A Botey, L Alvarez, E Poch, L Quintó, A Saurina, M Vera, C Piera, A Darnell.   

Abstract

Cystatin C is a nonglycosylated basic protein produced at a constant rate by all investigated nucleated cells. It is freely filtered by the renal glomeruli and primarily catabolized in the tubuli (not secreted or reabsorbed as an intact molecule). Because serum cystatin C concentration is independent of age, sex, and muscle mass, it has been postulated to be an improved marker of glomerular filtration rate (GFR) compared with serum creatinine level. We compared serum cystatin C level with other markers of GFR, such as serum creatinine level and creatinine clearance, and analyzed their variations based on iothalamate labeled with iodine 125 ((125)I-iothalamate) clearance ((125)I-ICl), used as the gold standard for GFR. The concentrations of the two different markers of GFR in patients with impaired renal function were classified according to (125)I-ICl. Twenty individuals with normal renal function ((125)I-ICl, 128 +/- 23 mL/min/1.73 m(2)) were used as the control group. Serum cystatin C level showed a greater sensitivity (93.4%) than serum creatinine level (86.8%). Also, serum cystatin C showed the greatest proportion of increased values in patients with impaired renal function (100%) compared with serum creatinine level (92.15%). Serum cystatin C levels started to increase to greater than normal values when GFR was 88 mL/min/1.73 m(2), whereas serum creatinine level began to increase when GFR was 75 mL/min/1.73 m(2). These data suggest that measurement of serum cystatin C may be useful to estimate GFR, especially to detect mild reductions in GFR, and therefore may be important in the detection of early renal insufficiency in a variety of renal diseases for which early treatment is critical.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10873868     DOI: 10.1053/ajkd.2000.8237

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  149 in total

1.  Cystatin C: our experience.

Authors:  Snezana Pavićević; Amira Peco-Antić
Journal:  Pediatr Nephrol       Date:  2005-06       Impact factor: 3.714

2.  Cystatin C-based CKD-EPI equations and N-terminal pro-B-type natriuretic peptide for predicting outcomes in acutely decompensated heart failure.

Authors:  Pedro J Flores-Blanco; Sergio Manzano-Fernández; Juan I Pérez-Calvo; Francisco J Pastor-Pérez; Francisco J Ruiz-Ruiz; Francisco J Carrasco-Sánchez; José L Morales-Rull; Domingo Pascual-Figal; Luis Galisteo-Almeda; James L Januzzi
Journal:  Clin Cardiol       Date:  2015-02-06       Impact factor: 2.882

3.  Cystatin C is associated with risk of venous thromboembolism in subjects with normal kidney function--the Tromsø study.

Authors:  Ellen E Brodin; Sigrid K Brækkan; Anders Vik; Jan Brox; John-Bjarne Hansen
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

4.  Relationship between serum cystatin C and hypertension among US adults without clinically recognized chronic kidney disease.

Authors:  Anoop Shankar; Srinivas Teppala
Journal:  J Am Soc Hypertens       Date:  2011-04-17

5.  Cystatin C identifies patients with stable chronic heart failure at increased risk for adverse cardiovascular events.

Authors:  Matthias Dupont; Yuping Wu; Stanley L Hazen; W H Wilson Tang
Journal:  Circ Heart Fail       Date:  2012-08-16       Impact factor: 8.790

6.  Cystatin C versus creatinine as a marker of glomerular filtration rate in the newborn.

Authors:  Milena Treiber; Breda Pecovnik-Balon; Maksimiljan Gorenjak
Journal:  Wien Klin Wochenschr       Date:  2006       Impact factor: 1.704

7.  The effect of including cystatin C or creatinine in a cardiovascular risk model for asymptomatic individuals: the multi-ethnic study of atherosclerosis.

Authors:  Hiroki Ito; Ivan V Pacold; Ramon Durazo-Arvizu; Kiang Liu; Michael G Shilipak; David C Goff; Russell P Tracy; Holly Kramer
Journal:  Am J Epidemiol       Date:  2011-08-30       Impact factor: 4.897

8.  Body mass index and preclinical kidney disease in Indian adults aged 40 years and above without chronic kidney disease.

Authors:  Charumathi Sabanayagam; Tien Yin Wong; Jiemin Liao; Sunil Sethi; Boon Wee Teo
Journal:  Clin Exp Nephrol       Date:  2014-02-14       Impact factor: 2.801

Review 9.  Screening for chronic kidney disease in HIV-infected patients.

Authors:  Michelle M Estrella; Derek M Fine
Journal:  Adv Chronic Kidney Dis       Date:  2010-01       Impact factor: 3.620

10.  Intima-media thickness of the common femoral artery as a marker of leg ulceration in sickle cell disease patients.

Authors:  Oluwagbemiga O Ayoola; Rahman A Bolarinwa; Uvie U Onakpoya; Tewogbade A Adedeji; Chidiogo C Onwuka; Bukunmi M Idowu
Journal:  Blood Adv       Date:  2018-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.